Comparative effect of vortioxetine and sertraline on clinical and inflammatory profile in Parkinson's disease with comorbid depression.

ABSTRACT:

Background

Preclinical and clinical studies suggest that the multimodal antidepressant vortioxetine may offer a valuable therapeutic option in the treatment of depression associated with neurological disorders, including Parkinson's disease (PD).

Objectives

To compare the effect of vortioxetine and the SSRI sertraline in the treatment of PD and comorbid depression, placing emphasis on peripheral inflammation markers.

Methods

This is an observational longitudinal study. We have recruited 33 patients affected by PD with comorbid depression, evaluated for motor and non-motor symptoms, depression, and peripheral and soluble markers of inflammation at baseline and at the end of antidepressant treatment. Patients were divided into two groups treated with either vortioxetine

SUBMITTER: Alborghetti M 

PROVIDER: S-EPMC12874709 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature